Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKEEGA vs SUTENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.
Treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (m CRPC) in combination with prednisone.
Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate,Advanced renal cell carcinoma (RCC),Adjuvant treatment of adult patients at high risk of recurrent RCC after nephrectomy,Progressive, well-differentiated pancreatic neuroendocrine tumors (p NET) in patients with unresectable locally advanced or metastatic disease
Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.
50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).
Terminal half-life: 17–30 hours (mean ~24 h); allows once-daily dosing but may require dose adjustment in renal impairment.
Terminal elimination half-life of sunitinib is 40-60 hours; for its primary active metabolite (SU12662) it is 80-110 hours. Steady-state achieved by day 14.
Niraparib is primarily metabolized by carboxylesterases (CEs) and to a lesser extent by CYP1A2 and CYP2D6. Abiraterone acetate is hydrolyzed to abiraterone, which is then metabolized by CYP3A4 and CYP2D6.
Primarily metabolized by CYP3A4; the major metabolite (N-desethyl sunitinib) is also active and is further metabolized by CYP3A4.
Renal: ~85% (primarily as unchanged drug); Biliary/Fecal: ~15%.
Renal: 16% of total radioactivity; Fecal: ~70% of total radioactivity (primarily as unchanged parent and metabolites).
~99% (bound primarily to α1-acid glycoprotein and albumin).
95% bound to human plasma proteins (albumin and alpha-1-acid glycoprotein).
Vd: ~1.5–2.0 L/kg (indicates extensive tissue distribution).
Apparent volume of distribution (Vd/F) is approximately 2230 L (enterprise, not weight-adjusted). The Vd is large, indicating extensive extravascular distribution.
Oral: ~90% (high oral bioavailability).
Oral bioavailability is approximately 40% (range 30-50%).
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). Not recommended for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
No adjustment for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min); avoid use in severe impairment (Cr Cl <30 m L/min) due to lack of data.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment; but monitor closely for toxicity.
Child-Pugh Class A: 50 mg daily; Class B: reduce to 37.5 mg daily; Class C: not recommended.
Safety and efficacy not established in pediatric patients; no recommended dose.
Not approved for pediatric use; no established weight-based dosing.
No specific dose adjustment required. Clinical studies included patients ≥65 years; increased risk of adverse effects such as hypertension, hypokalemia, and fatigue. Monitor renal function and electrolytes regularly.
No specific dose adjustment; monitor renal function and blood pressure more frequently due to increased sensitivity to adverse effects.
AKEEGA can cause severe and persistent hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess, especially in patients with renal impairment. Monitor blood pressure, serum potassium, and fluid status regularly.
Hepatotoxicity: Severe, sometimes fatal hepatotoxicity has been observed. Monitor liver function tests before and during treatment. Interrupt or discontinue SUTENT and manage as appropriate.
Hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess,Adrenocortical insufficiency,Hepatotoxicity,Cardiovascular effects including QT prolongation,Bone marrow suppression (anemia, thrombocytopenia, neutropenia),Fetal harm if used during pregnancy
Hepatotoxicity: Monitor liver function tests before and during therapy; interrupt or discontinue for severe hepatotoxicity.,Cardiovascular events: Hypertension, QT prolongation, left ventricular dysfunction, including heart failure; monitor blood pressure and cardiac function.,Hemorrhage: Severe, sometimes fatal hemorrhagic events; monitor for signs and symptoms.,Thyroid dysfunction: Monitor thyroid function; manage with thyroid hormone replacement as needed.,Adrenal insufficiency: Reported; monitor for symptoms.,Proteinuria: Monitor urine protein; discontinue for nephrotic syndrome.,Wound healing complications: Withhold therapy for at least 24 days prior to elective surgery.,Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue if signs/symptoms occur.,Thrombotic microangiopathy (TMA): Reported; discontinue if TMA occurs.
Concomitant use with strong CYP3A4 inducers,Severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease,History of hypersensitivity to niraparib, abiraterone, or any excipient
None known.
Avoid food and beverages containing grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and may increase abiraterone exposure. Take AKEEGA on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid high-fat meals as they increase abiraterone absorption.
Avoid grapefruit and grapefruit juice during treatment. St. John's wort may reduce efficacy. No other significant interactions.
AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abiraterone acetate is also associated with fetal risks. First trimester exposure may cause embryofetal lethality and teratogenicity. Second and third trimester exposure may impair fetal adrenal function and androgen-dependent development.
Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm delivery due to antiangiogenic effects. Avoid use in pregnancy.
No data on the presence of niraparib or abiraterone in human milk, effects on breastfed infants, or milk production. Due to the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 month after the last dose. M/P ratio is unknown.
No human data available; M/P ratio unknown. Sunitinib and its metabolites are excreted in rat milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 4 weeks after the last dose.
No specific dose adjustments are established during pregnancy as AKEEGA is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate dose adjustments if used inadvertently, but no data are available. If exposure occurs, cautious monitoring and individualized dosing are recommended.
No pharmacokinetic data in pregnancy; dose adjustments are not established. Given teratogenicity, use is not recommended. If unavoidable, consider reduced dose (e.g., 37.5 mg daily) with close monitoring, but safety and efficacy are not validated.
AKEEGA (niraparib and abiraterone acetate) is indicated for BRCA-positive metastatic castration-resistant prostate cancer. Monitor for myelosuppression (CBC at baseline and monthly), hypertension (BP weekly for first month then monthly), hypokalemia, and hepatotoxicity (LFTs at baseline and monthly). CYP3A4 inhibitors increase abiraterone exposure; avoid strong inhibitors or reduce dose. Corticosteroid co-administration (prednisone 5 mg BID) is required to manage mineralocorticoid excess. Niraparib may cause fetal harm; confirm pregnancy status before initiation.
Monitor for hypertension and proteinuria; manage with antihypertensives. Check thyroid function before and during therapy due to risk of hypothyroidism. Monitor liver enzymes and cardiac function, especially in patients with pre-existing conditions. Dose adjustments needed for hepatic impairment (Child-Pugh Class C).
Take tablets on an empty stomach, at least 1 hour before or 2 hours after a meal.,Swallow tablets whole; do not crush or chew.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit during treatment.,Use effective contraception during treatment and for 4 months after the last dose for females and 3 months for males.,Report signs of bone marrow suppression: fever, bruising, bleeding, or unusual tiredness.,Report symptoms of high blood pressure: severe headache, blurred vision, or chest pain.,Take prednisone exactly as prescribed; do not stop abruptly.,Avoid pregnancy; discuss fertility preservation options before starting treatment.,Take missed doses if within 12 hours of scheduled time; otherwise skip and resume next day.,Store at room temperature; keep in original container.
Take with or without food, but avoid grapefruit juice.,Report any signs of bleeding, unusual bruising, or fatigue.,Monitor blood pressure regularly and report high readings.,Watch for changes in skin color (yellowing or darkening) or nail changes.,Use effective contraception during treatment and for at least 4 weeks after stopping.,Avoid sun exposure; use sunscreen and protective clothing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKEEGA vs SUTENT, answered by our medical review team.
AKEEGA is a Antineoplastic Combination that works by Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.. SUTENT is a Tyrosine Kinase Inhibitor Antineoplastic that works by Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKEEGA and SUTENT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKEEGA is: Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.. The standard adult dose of SUTENT is: 50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKEEGA and SUTENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKEEGA is classified as Category C. AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abirate. SUTENT is classified as Category C. Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth rest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.